The Trump administration's COVID-19 vaccine and drug initiative, Operation Warp Speed, has committed to purchase 100 million doses of Sanofi and GlaxoSmithKline's COVID-19 vaccine candidate in a deal worth up to $2.1 billion, the largest award given so far to a vaccine developer. The government has the option to buy an additional 500 million doses.
Two of Siemens' blood tests, the Attelica COV2G and the ADVIA Centaur COV2G, are the first semi-quantitative assays to be approved by the FDA for use in the US for COVID-19 antibodies. The tests are able to measure the quantity of antibodies a patient has against the SARS-CoV-2 virus.
The FDA has given emergency use authorization to Clinical Reference Laboratory for its saliva-based COVID-19 test.
Seven companies were chosen by the NIH to receive funding for new technologies to boost their testing capacities and help them ramp up production of millions of coronavirus rapid tests to be made available by September 2020. A total of $248.7 million will be invested and shared by Mesa Biotech, Quidel and Talis Biomedical, Fluidigm, Ginkgo Bioworks, Helix OpCo and Mammoth Biosciences.
Siemens Healthineers will acquire medical device and software maker Varian Medical Systems in a deal worth $16.4 billion.
Researchers from the University Hospitals Leicester NHS Trust and Nottingham Trent University in the UK have created a blood test for prostate cancer that can determine the stage and progression of the disease with 99% accuracy.
Sanofi ended its collaboration with Japan's Daaichi to develop a pediatric pentavalent vaccine. The companies were hoping to improve efforts in Japan to develop the vaccines as Japan is behind the rest of the world in their production.